Targeted therapies have been previously reported to show marked antitumor effects against advanced NSCLC that express molecular driver oncogenes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c‐Ros oncogene 1 (ROS1),5, 6, 7, 8 including in elderly populations, resulting in the development of individualized treatment strategies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.